Kancera AB (publ)

Stockholm Stock Exchange KAN.ST

Kancera AB (publ) Price to Sales Ratio (P/S) on January 14, 2025: 118.38

Kancera AB (publ) Price to Sales Ratio (P/S) is 118.38 on January 14, 2025, a -63.43% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.
  • Kancera AB (publ) 52-week high Price to Sales Ratio (P/S) is 333.84 on February 06, 2024, which is 182.00% above the current Price to Sales Ratio (P/S).
  • Kancera AB (publ) 52-week low Price to Sales Ratio (P/S) is 89.79 on November 13, 2024, which is -24.16% below the current Price to Sales Ratio (P/S).
  • Kancera AB (publ) average Price to Sales Ratio (P/S) for the last 52 weeks is 179.46.
Key data
Date Price to Sales Ratio (P/S) Price to Book Ratio (P/B) Dividend Yield Free Cash Flow Yield
Market news
Loading...
Stockholm Stock Exchange: KAN.ST

Kancera AB (publ)

CEO Mr. Peter Selin
IPO Date Feb. 25, 2011
Location Sweden
Headquarters Karolinska Institutet Science Park
Employees 5
Sector Health Care
Industries
Description

Kancera AB (Publ) develops drugs for inflammatory diseases and cancer in Sweden and internationally. The company is developing small molecule drug candidates KAND567, which is in phase IIa clinical trial for inflammatory heart disease following infarction, as well as KAND145, which is in phase I study in healthy subjects to document desired dose levels against cancer; and Phase IIa study for the treatment of ovarian cancer. It also develops HDAC for the treatment of nerve inflammation and pain; and ROR1 inhibitors for the treatment of solid tumors and blood cancers. Kancera AB (Publ) was founded in 2010 and is based in Solna, Sweden.

Similar companies

BINV.ST

BioInvent International AB (publ)

USD 2.74

1.67%

COMBI.ST

CombiGene AB (publ)

USD 0.21

0.68%

CANTA.ST

Cantargia AB (publ)

USD 0.15

0.09%

StockViz Staff

January 15, 2025

Any question? Send us an email